Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felbinac Trometamol Injection for Postoperative Pain in Gynecology
NCT05297669Phase 3Completed
- Sponsor
- Yiling Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative pain comparing Felbinac Trometamol with Placebo (2 arms). Primary endpoint: 24 hours (h) total morphine consumption. Started Jul 2021; status: completed.
02
Drugs
felbinac
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05297669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297669.